Education
About Us
Working with TipRanks
Follow Us
Champions Oncology (CSBR)
:CSBR
Top Page
Champions Oncology
(NASDAQ:CSBR)
Rating:49Neutral
Price Target:―
Champions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$88.86M
Dividend YieldN/A
Average Volume (3M)35.21K
Price to Earnings (P/E)20.2
Beta (1Y)0.30
Revenue Growth19.03%
EPS GrowthN/A
CountryUS
Employees210
SectorHealthcare
Sector Strength38
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding13,777,170
10 Day Avg. Volume52,997
30 Day Avg. Volume35,209
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda11.23
Forecast
1Y Price Target
$12.00Price Target Upside88.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology Business Overview & Revenue Model
Company DescriptionChampions Oncology (CSBR) is a biotechnology company focused on advancing personalized medicine in oncology. The company operates primarily in the life sciences sector, offering innovative drug discovery and development solutions. Its core services include the development and utilization of advanced technologies and platforms to assist pharmaceutical companies and academic institutions in accelerating the development of anti-cancer drugs and therapies.
How the Company Makes MoneyChampions Oncology generates revenue through its personalized oncology solutions and collaboration with pharmaceutical companies. Its key revenue streams include the sale of its proprietary TumorGraft Technology Platform, which facilitates the creation of personalized cancer treatment plans by implanting human tumors in mice for drug testing. Additionally, the company earns income from its drug discovery and development services, which include preclinical studies and clinical trials. Strategic partnerships and collaborations with major pharmaceutical companies further bolster its earnings by providing opportunities for joint research and development projects.
Champions Oncology Earnings Call Summary
Earnings Call Date:Jul 23, 2025
(Q4-2025)
| % Change Since: -17.68%|
Next Earnings Date:Sep 10, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive turnaround for Champions Oncology, highlighted by record revenue, a return to profitability, and successful data licensing deals. However, challenges persist, such as a decline in Q4 revenue and gross margin, alongside ongoing market constraints.Q4-2025 Updates
Positive Updates
Record Revenue and Return to Profitability
Champions Oncology achieved a record total revenue of $57 million, marking a 14% increase from the previous year, and returned to profitability with an adjusted EBITDA of $7.1 million compared to a loss of $3.9 million in fiscal 2024.
Inaugural Data Licensing Deals
Champions closed its first data licensing deal in the third quarter, contributing to a total of $4.7 million in data revenue and showcasing the potential of its multi-omic PDX databank.
Launch of Radiopharmaceutical Services
The company launched a new radiopharmaceutical services platform, offering integrated workflows and therapeutic efficacy testing across a range of isotopes.
Strong Cash Position
Champions ended the year with $9.8 million in cash, up from $2.6 million, and remains debt-free, indicating a strong financial position.
Negative Updates
Q4 Revenue Decline
Fourth-quarter revenue was $12.1 million, down from $14 million in the previous year, resulting in a GAAP operating loss of $2 million.
Gross Margin Decline
The gross margin for the fourth quarter declined to 41%, down from 48% in Q4 2024, due to lower revenue on a relatively unchanged cost base.
Challenging Market Conditions
Despite signs of recovery, the biotech and pharma sectors continue to face constrained R&D budgets, impacting market conditions.
Company Guidance
During the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call, the company reported significant growth metrics, highlighting a 14% year-over-year increase in total revenue to a record $57 million, driven by a 4% increase in research services revenue and $4.7 million from data licensing deals. Adjusted EBITDA swung from a loss of $3.9 million in fiscal 2024 to a gain of $7.1 million. The fourth quarter saw a revenue dip to $12.1 million, with an operating loss of $2 million, partially due to $800,000 in noncash expenses. Gross margin for the year improved to 50% from 42%, attributed to high-margin data revenue and operational efficiencies, despite a dip to 41% in Q4. Investments in sales and marketing rose by $500,000, although R&D and G&A expenses saw modest declines. Champions ended the year with $9.8 million in cash, up from $2.6 million, and remains debt-free, projecting cash neutrality in the subsequent quarter. The company remains optimistic about fiscal 2026, anticipating sequential revenue and adjusted EBITDA growth.Champions Oncology Financial Statement Overview
Summary
Champions Oncology's financial statements depict a company facing significant challenges in revenue stability and cash management, despite some improvements in equity and net income. The high leverage and inconsistent profit margins reflect potential risks, while cash flow issues underscore liquidity concerns. Overall, the company is in a transitional phase, showing both vulnerabilities and some recovery indicators.Income Statement
The company exhibits a volatile income statement with a negative gross profit margin in TTM, indicating more costs than revenue. Despite a positive net income in TTM, the revenue growth rate is negative, showing declining sales over time. Margins are inconsistent, with significant fluctuations in EBIT and EBITDA margins. The overall income statement suggests instability in revenue generation and cost management.40
Negative
Balance Sheet
The balance sheet reveals a concerning debt-to-equity ratio, indicating high leverage. However, the TTM data shows improved stockholders' equity, suggesting a recovery trend. ROE is positive in TTM, reflecting recent profitability. The equity ratio remains low, indicating potential financial risk due to dependence on liabilities. The balance sheet points to a moderate risk profile with some signs of recovery.45
Neutral
Cash Flow
Cash flow analysis shows negative free cash flow growth in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash outflows even with positive net income. This trend suggests problems in converting earnings into cash. The cash flow statement highlights liquidity challenges and inefficiencies in cash operations.35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 50.16M | 53.87M | 49.11M | 41.04M |
| Gross Profit | -28.39M | 20.75M | 24.34M | 25.48M | 19.57M |
| EBITDA | 4.55M | -5.05M | -2.07M | 2.23M | 366.00K |
| Net Income | 4.70M | -7.28M | -5.33M | 548.00K | 362.00K |
Balance Sheet | |||||
| Total Assets | 32.34M | 26.13M | 34.31M | 35.38M | 27.59M |
| Cash, Cash Equivalents and Short-Term Investments | 9.79M | 2.62M | 10.12M | 9.01M | 4.69M |
| Total Debt | 6.11M | 7.43M | 8.60M | 9.47M | 9.60M |
| Total Liabilities | 28.57M | 28.04M | 29.68M | 26.28M | 20.16M |
| Stockholders Equity | 3.77M | -1.90M | 4.64M | 9.10M | 7.43M |
Cash Flow | |||||
| Free Cash Flow | 7.00M | -6.97M | 1.08M | 4.11M | -4.96M |
| Operating Cash Flow | 7.39M | -6.14M | 3.96M | 6.50M | -1.68M |
| Investing Cash Flow | -389.00K | -836.00K | -2.87M | -2.38M | -3.17M |
| Financing Cash Flow | 170.00K | -527.00K | 11.00K | 207.00K | 1.20M |
Champions Oncology Technical Analysis
Negative
6.38
Price Trends
7.23
Negative
7.48
Negative
7.52
Negative
Market Momentum
-0.37
Positive
39.57
Neutral
22.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.38 is below the 20-day moving average (MA) of 7.34, below the 50-day MA of 7.23, and below the 200-day MA of 7.52, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 39.57 is Neutral, neither overbought nor oversold. The STOCH value of 22.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our Chief Executive Officer resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely affected by political, economic, and military instability in Israel. Q1, 2024
Champions Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $350.94M | ― | -91.44% | ― | -2.04% | 83.49% | |
52 Neutral | $142.72M | ― | -45.55% | ― | 98.56% | 37.97% | |
52 Neutral | $124.75M | ― | -24.73% | ― | -1.02% | -8.59% | |
51 Neutral | $7.39B | 0.42 | -62.86% | 2.37% | 15.61% | -1.93% | |
49 Neutral | $88.86M | 20.16 | 503.05% | ― | 19.03% | ― | |
46 Neutral | $101.45M | ― | -59.45% | ― | ― | 48.92% | |
30 Underperform | $146.21M | ― | -744.59% | ― | ― | 27.65% |
* Healthcare Sector Average
Performance Comparison
CSBR
Champions Oncology
6.45
1.82
39.31%
TNXP
Tonix Pharma
47.70
-0.30
-0.62%
ZNTL
Zentalis Pharmaceuticals
1.41
-1.90
-57.40%
CCCC
C4 Therapeutics
2.01
-3.78
-65.28%
SEER
Seer
2.12
0.39
22.54%
ELTX
Elicio Therapeutics
9.14
4.46
95.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.